SCHEMBL4515430

SCHEMBL4515430

Cc1cc(C)n(-c2ccc(F)cc2)n1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
MAPK1 P28482 1/20 0.60
HTT P42858 1/20 0.60
RECQL P46063 1/20 0.60
SLC34A1 Q06495 2/20 0.55
POLB P06746 2/20 0.53
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
TERT O14746 1/20 0.47
KCNJ6 P48051 1/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29120365 0.89 MAPT (0.67) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL10169870 0.83 MAPT (0.61) MAPTL3MBTL1ALDH1A1HPGDNPSR1
SCHEMBL29280344 0.82 MAPT (0.59) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL6284416 0.81 CYP1A2 (0.68) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL19641736 0.81 MAPT (0.47) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL25218627 0.81 MAPT (0.47) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL14749859 0.81 NPC1 (0.50) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL30490040 0.81 MAPT (0.47) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL15825685 0.81 MAPT (0.43) MAPTL3MBTL1MAPK1HTTRECQL
SCHEMBL14478805 0.80 MAPT (0.57) MAPTL3MBTL1ALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114292234-B Preparation method of pyrazole derivative 南方海洋科学与工程广东省实验室(湛江) 2024-05-14 CN disclosed
WO-2023104035-A1 SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 英矽智能科技(上海)有限公司 2023-06-15 WO disclosed
CN-114292234-A Preparation method of pyrazole derivative 南方海洋科学与工程广东省实验室(湛江) 2022-04-08 CN disclosed
EP-3400220-B1 PYRAZOLE DERIVATIVES HUA MEDICINE SHANGHAI LTD (CN) 2021-03-24 EP disclosed
US-10941132-B2 Pyrazole derivatives HUA MEDICINE (SHANGHAI) LTD. (CN) 2021-03-09 US disclosed
EP-3080087-B1 N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORP (US) 2019-05-22 EP disclosed
US-20190002432-A1 PYRAZOLE DERIVATIVES HUA MEDICINE (SHANGHAI) LTD. (CN) 2019-01-03 US disclosed
EP-2934536-B1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME (US) 2017-09-27 EP disclosed
WO-2017117708-A1 PYRAZOLE DERIVATIVES HUA MEDICINE (SHANGHAI) LTD. (CN) 2017-07-13 WO disclosed
US-9695198-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-04 US disclosed
US-20170029535-A1 REGULATION OF A CONTROLLED RADICAL POLYMERIZATION OF ACRYLATES BY LIGHT DOW GLOBAL TECHNOLOGIES LLC 2017-02-02 US disclosed
US-20150368269-A1 Factor IXa Inhibitors MERCK SHARP & DOHME CORP. (US) 2015-12-24 US disclosed
US-9081283-B2 Spatial and temporal control of brush formation on surfaces THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-07-14 US disclosed
US-9081283-B2 Spatial and temporal control of brush formation on surfaces THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-07-14 US disclosed
WO-2014099694-A1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-06-26 WO disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
EP-1956020-A2 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity SMITHKLINE BEECHAM PLC (GB) 2008-08-13 EP disclosed
EP-1385845-B1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM PLC (GB) 2008-01-09 EP disclosed
CN-101094832-A Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases ASTRAZENECA AB (SE) 2007-12-26 CN disclosed
EP-1406897-B1 COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2007-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10941132-B2 Pyrazole derivatives GRM5, GRIK5, GRIN2C MAPT 674/4885L3MBTL1 3222/4885MAPK1 814/4885
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 MAPT 3699/4885L3MBTL1 4844/4885MAPK1 672/4885
US-20150368269-A1 Factor IXa Inhibitors F9, TFPI, F13B MAPT 4555/4885L3MBTL1 4586/4885MAPK1 2764/4885
US-20190002432-A1 PYRAZOLE DERIVATIVES GRM5, GRIK5, GRIN2C MAPT 674/4885L3MBTL1 3222/4885MAPK1 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.